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Th   e human gut is colonized by a large variety of microbial 
species that diff  er among healthy people [1,2]. Owing to 
the direct links between the human microbiome and the 
immune system, disruptions of the microbial ecology of 
the  microbiome  (dysbioses)  have  been  implicated  in 
many diseases, particularly those involving systemic or 
localized infl  ammation (Figure 1) [3-6]. Th   is raises two 
exciting possibilities for the translation of basic research 
to  clinical  practice.  Th   e  fi  rst  is  the  use  of  the  human 
microbiome as a diagnostic tool to predict disease risk, 
patient outcomes or response to treatment. Th   e second is 
the  eventual  use  of  the  microbiome  as  a  therapeutic 
target, since microbial composition and metabolic activity 
are modifi  able with relative ease by factors such as diet 
[7-9], the environment [10] and pharmaceuticals [11]. To 
realize this potential, however, a deeper understanding of 
biomolecular  activity  in  these  microbial  communities 
will  need  to  be  developed  by  means  of  functional 
profi  ling of the human microbiome.
Th   e  gut  microbiome  has  both  the  greatest  microbial 
density  in  the  human  body  and  is  the  site  at  which 
microbes are most exposed to the immune system. Th   is 
has  led  to  its  implication  in  a  range  of  autoimmune 
diseases aff  ecting the gastrointestinal tract [12], such as 
infl  ammatory bowel disease [13], colorectal cancer [4], 
type 1 diabetes [5] and metabolic syndromes [14]. Owing 
to  its  extensive  interaction  with  the  systemic  immune 
system, however, the gut microbiome also contributes to 
the activity of the enteric nervous system (neuro  gastro-
enterological  disorders  [15]),  extra-intestinal  tissues 
(rheumatoid arthritis [16], allergy and atopy [17]), and 
the  skin  (atopic  dermatitis  [18]).  In  many  of  these 
diseases, genetic and environmental factors are known to 
play  a  role,  but  the  biomolecular  mechanisms  linking 
microbial  communities  to  disease  are  still  unknown. 
Further  functional  profi  ling  by  metagenomics,  meta-
trans  criptomics  and  additional  modalities  will  thus  be 
required  to  understand  how  and  why  microbial  genes 
and genome compositions, pathway and transcript acti-
vities, and metabolic processes are altered in infl  am  ma-
tory conditions, health and disease.
Abstract
The microbial residents of the human gut are a major 
factor in the development and lifelong maintenance 
of health. The gut microbiota diff  ers to a large degree 
from person to person and has an important infl  uence 
on health and disease due to its interaction with 
the human immune system. Its overall composition 
and microbial ecology have been implicated in 
many autoimmune diseases, and it represents a 
particularly important area for translational research 
as a new target for diagnostics and therapeutics in 
complex infl  ammatory conditions. Determining the 
biomolecular mechanisms by which altered microbial 
communities contribute to human disease will be 
an important outcome of current functional studies 
of the human microbiome. In this review, we discuss 
functional profi  ling of the human microbiome using 
metagenomic and metatranscriptomic approaches, 
focusing on the implications for infl  ammatory 
conditions such as infl  ammatory bowel disease and 
rheumatoid arthritis. Common themes in gut microbial 
ecology have emerged among these diverse diseases, 
but they have not yet been linked to targetable 
mechanisms such as microbial gene and genome 
composition, pathway and transcript activity, and 
metabolism. Combining these microbial activities with 
host gene, transcript and metabolic information will be 
necessary to understand how and why these complex 
interacting systems are altered in disease-associated 
infl  ammation.
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© 2013 BioMed Central LtdAs in single-species systems biology, various meta’omic 
tools can provide insight into multiple levels of biological 
regulation in the microbiome, including the detection of 
microbial organisms, genes, variants, pathways or meta-
bolic functions characterizing the microbial community 
in an uncultured sample, such as fecal samples or mouth 
rinses.  Microbial  ecology  has  most  extensively  been 
studied using targeted 16S rRNA gene sequencing, but 
this  provides  only  indirect  information  on  molecular 
activities and will not be the focus of this review. Instead, 
we  will  focus  on  approaches  that  provide  more  direct 
information on biomolecular function within a microbial 
community, such as metagenomic shotgun sequencing of 
whole-community DNA to provide a survey of the overall 
genetic  potential  of  a  microbiome.  Transcriptional 
activity  can  likewise  be  assayed  by  metatranscriptomic 
cDNA sequencing to identify regulatory activity occur-
ring  rapidly  in  response  to  changes  in  environment. 
Whole-community  metaproteomics  and  metabolomics 
are  currently  less  common,  but  each  again  captures 
Figure 1. A model of functional dysbiosis in the human gut microbiome during initiation and progression of complex disease. Although 
many current studies focus on microbial composition shifts that occur subsequent to disease establishment, it is critical to differentiate functional 
from structural changes in the microbiome and their distinct patterns in early versus late disease. (a) An illustration of microbial community 
structural changes during complex disease progression. Ordinations such as principle coordinate analysis and multidimensional scaling are 
commonly used to qualitatively visualize microbial community structure among multiple samples (for example, cases and controls). Ordinations 
project distance measures such as beta diversity among samples into fewer dimensions in such a way that the patterns of greatest change occur on 
the primary axes (here, x and y). However, particularly in early disease, case/control status is frequently not among the factors with most influence 
on inter-subject microbial variation. Conversely, later-stage inflammation can have a very large effect on microbial structure, causing other sources 
of variation to become visually less apparent. (b) Functional profiles of gut microbial communities remain more stable among individuals in health 
than do microbial profiles, and they can likewise show more concerted differential responses in early and late disease stages. In this illustration, ‘case’ 
subject samples exhibit expansion of specific metagenomically encoded functions in their microbial communities during progressive phases of 
inflammation, as reported in [32]. (c) Representative host histology in different phases of the inflammatory response in Crohn’s colitis. Colonic crypts 
(ring structures) are gradually destroyed by immune infiltration as colitis progresses. Images show transverse sections of human colonic mucosa 
stained with hematoxylin and eosin; 100 µm scale bars are included for reference (images provided by WSG). CDAC, Clostridium difficile-associated 
diarrhea; PC, principal coordinate.
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molecular  activity  [19].  In  this  review,  we  discuss 
functional profiling of the human gut microbiome using 
metagenomics and metatranscriptomics in inflammatory 
diseases to gain insight into the microbial species, path-
ways and metabolites, as well as host genes, transcripts 
and  pathways  that  are  altered  during  chronic  inflam-
matory conditions.
The gut microbiome
Humans  are  born  almost  sterile,  but  during  birth  and 
early  development  they  are  rapidly  and  dynamically 
colonized by microbes throughout the body [20]. These 
reside primarily in the gut and include bacteria, viruses 
and, to a lesser degree, archaea and eukaryotic microbes 
[1,21].  The  number  of  microbial  genes  involved  in 
establishing and maintaining the community’s ecology is 
immense, totaling 5,000,000 or more [1,21]. This genetic 
repertoire  interacts  with  that  of  the  host  and  with 
environmental factors to create and maintain a cellular 
system  with  a  metabolic  and  regulatory  capacity  com-
parable to that of complex human tissues [22]. Indeed, in 
the absence of microbes, neither host gut physiology nor 
the  immune  system  develop  normally  [23].  The 
distribution  of  microbes  throughout  the  gut  is  highly 
struc  tured and dedicated to a variety of biological func-
tions (Box 1).
Inflammation seems to exert effects to which the gut 
microbiota is particularly sensitive, and studies with the 
mucosal disruptant dextran sodium sulfate, which elicits 
colonic  inflammation  in  wild-type  mice,  have  demon-
strated  that  inflammation  affects  the  microbiota  [24]. 
Inflammation  results  in  a  cascade  of  cellular  and 
molecular effectors that can be directly bactericidal or 
generate substantial environmental stress for a microbial 
community. In retrospect, it is intuitive that inflammatory 
bowel  disease,  celiac  disease,  rheumatoid  arthritis  and 
other chronic inflammatory conditions represent one of 
the  largest  families  of  known  microbiome-perturbing 
human  diseases.  The  additional  roles  of  symbiotic 
microbial stimulation of innate and adaptive immunity in 
the gut and training of systemic immunity are much less 
well understood, but they undoubtedly function in the 
triggering, maintenance and remission of inflammatory 
conditions.
Gut microbes in chronic inflammatory and 
autoimmune disease
Inflammatory bowel diseases
It has long been accepted that the inflammatory bowel 
diseases - Crohn’s disease and ulcerative colitis - occur in 
conjunction with a dysregulated host immune response 
to the normal gut microbiome, and include strong genetic 
components  [25].  Recent  genome-wide  association 
studies (GWAS) have been very successful in revealing 
the  responsible  human  genes  [3].  However,  disease-
causing functional defects have only been explained for a 
few genes (for example, NOD2, IL23R), which are also 
intimately  tied  to  the  microbiome  by  crucial  roles  in 
controlling microbial infiltration in the gut [26].
Assessing  microbial  functional  responses  in  tandem 
with additional human genetic risk variants may help to 
better identify their functional consequences in vivo. For 
example, low plasma levels of vitamin D (which inhibit 
pro-inflammatory p38 kinase signaling [27], affect innate 
immune function [28] and may promote development of 
T regulatory cells [29]) are associated with an increased 
risk of Crohn’s disease [25]. The gut microbiome can alter 
both the distribution and expression of vitamin D recep-
tors  in  the  gut  [30],  suggesting  that  natural  microbial 
variation  is  a  contributing  influence  on  vitamin  D 
metabolism. Dietary fiber, which is metabolized by the 
gut  microbiota  to  anti-inflammatory  short-chain  fatty 
acids (SCFAs), has been found to be protective against 
inflammatory bowel disease in some studies [25]. Both 
low vitamin D levels and dietary fiber intake represent a 
host-microbe  metabolic  interaction  that  potentially 
affects inflammatory bowel disease onset or activity.
The  widely  observed  reduction  in  diversity  of  gut 
microbial ecology in inflammatory bowel disease [31,32] 
may  be  a  consequence  of  more  specific  functional 
changes.  For  example,  increased  levels  of  Enterobac-
teriaceae may be the result of differences in this taxon’s 
ability  to  tolerate  inflammation-associated  redox  stress 
[33],  and  SCFA-producing  Clostridia  may  be  out  com-
peted  by  more  generalist  or  opportunistic  Enterobac-
teriaceae,  resulting  in  decreased  microbial  SCFA  pro-
duction  and  contributing  to  a  self-reinforcing  pro-
inflammatory state incorporating both host immune and 
microbial  metabolic  components  [32].  Such  host-
microbe and microbe-microbe regulatory feedback loops 
provide  novel  potential  targets  for  pharmaceutical  and 
probiotic  development,  since  both  the  introduction  of 
specific microbes [34] and the disruption of individual 
microbial processes such as redox metabolism [35] have 
the potential to mitigate inflammatory processes in the 
gut.
Rheumatoid arthritis
Rheumatoid arthritis is a systemic inflammatory disorder 
that manifests as an inflammatory response to synovial 
tissues. Recent studies have associated the oral microbial 
community with the disease, with rheumatoid arthritis 
patients having a higher prevalence of periodontitis and 
tooth loss [36]. In the gut, several studies have shown 
that  diet  can  have  a  therapeutic  effect  on  rheumatoid 
arthritis  in  conjunction  with  decreased  inflammation 
[37]. Some initial studies have been performed to gain 
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in  the  intestinal  microbiome  and  their  impact  on 
inflammation and immune responses [38]. For example, 
Lactobacillus bifidus was shown to trigger arthritis in a 
mouse model (IL-1-receptor-antagonist-deficient mice), 
which was specifically driven by an imbalance in T-cell 
homeostasis  and  mediated  through  Toll-like  receptor 
(TLR2 and TLR4) signaling [39]. In this mouse model, 
which  is  known  to  spontaneously  develop  an  auto-
immune T-cell-mediated arthritis due to excessive inter-
leukin (IL)-1 signaling [40], TLR2 and TLR4 were involved 
in  the  expression  of  autoimmune  arthritis.  Specifically, 
TLR2 slowed the progression of arthritis by controlling 
the  function  of  T  regulatory  cells  and  regulating 
interferon (IFN)-γ-producing T helper 1 (Th1) cells, and 
TLR4 increased the severity of the disease by modulating 
the T helper 17 (Th17)-cell population and IL-17 produc-
tion. Another study found that autoimmune arthritis was 
strongly  attenuated  in  a  K/BxN  mouse  model  under 
germ-free  conditions,  accompanied  by  reductions  in 
serum autoantibody titers, splenic autoantibody-secret-
ing  cells,  germinal  centers,  and  the  splenic  Th17  cell 
population [16]. The authors observed that their mouse 
model had a dearth of IL-17-producing T cells, which 
could be reversed by introducing segmented filamentous 
bacteria  into  the  gut  of  germ-free-housed  mice, 
provoking  rapid  onset  of  the  disease.  Taken  together, 
these studies suggest that both the oral and gut micro-
biome may trigger rheumatoid arthritis by inciting local 
inflammatory responses in the host, but do not elucidate 
what mechanism might be at play in systematizing this 
response or targeting it to the synovium.
Allergy and atopy
The role of the microbiome in allergy and asthma is the 
foundation of the widely recognized ‘hygiene hypothesis’, 
which  states  that  a  combination  of  improved  hygiene, 
frequent use of antibiotics, or vaccinations may lead to 
reduced bacterial and viral infections, and to an altered 
immune system that responds inappropriately to innocu-
ous  substances  [41].  Recent  functional  studies  of  sym-
biotic microbes in these conditions have been pri  marily 
epidemiological,  and  have  targeted  environmental  risk 
and  preventive  factors  such  as  lifestyle,  infections  and 
diet [42]. Perhaps the strongest results have arisen from 
investigations  of  early  life  exposures  to  environmental 
microbes,  establishing  a  link  between  home  allergen 
levels, lymphocyte proliferation and wheeze in children 
at high risk for asthma [43]. In several such studies, early 
life ’urban’ allergen exposures have been associated with 
later  asthma  and  allergy  risk,  whereas  environmental 
microbial exposures have generally been protective.
Box 1. Influences on gut microbiota structure and function
Overall, the gut microbiota comprises residents of the stomach, small intestine and large intestine [98]. However, owing to pH stress and 
bile salt toxicity, microbial biomass is very low before the ileum. The vast majority (more than 99%) of the gut microbiome is found in 
the colon, where (among other activities) it breaks down indigestible fibers and ferments them into SCFAs. These are an essential fuel 
for colonocytes, maintain colon health, and provide approximately 10% of dietary energy from a Western diet. The colon contains by far 
the most microbial cells in a typical human body, dominated by the Bacteroidetes and Firmicutes phyla, with lesser but still important 
consortia of Proteobacteria, Actinobacteria, other bacterial clades, and Archaea. Both stool samples and biopsies have been extensively 
investigated as representatives of the colonic mucosal and luminal communities; comparable taxa are detected regardless of sample origin 
but in different relative abundances [32], reflecting microbial dispersion and niche specialization.
The composition of the gut microbiome is influenced by both genetics and environmental factors such as diet [6] and age [32]. For 
example, monozygotic twins were found to be concordant for carriage of Methanobrevibacter smithii at a much higher rate than dizygotic 
twins (74% versus 14%) [99], although it is difficult to distinguish this effect from that of co-habitation [100]. The dynamics of microbial 
responses to perturbations are particularly critical to consider during early life and beyond [101-103], and longitudinal sampling of 
complex communities is an active area of research [104].
The gut microbiota seems to be resilient to short-term dietary change, as even profound shifts in diet (such as from a high-fat/high-protein 
to a low-fat/low-protein diet) tend to quickly change the relative abundance of microbial taxa but not their presence or absence [105,106]. 
However, humans from different environments (with correspondingly different long-term diets) do maintain distinct microbiomes. For 
instance, a recent study compared healthy children from Italy and Burkina Faso - the latter of whom consumed a much higher-fiber diet 
and very little meat. The microbiota of the children from Burkina Faso was much more phylogenetically diverse and had approximately 
fourfold higher fecal butyrate concentrations, indicating microbial communities more efficient at extracting nutrients from fiber than those 
of the Italian children [9]. Interestingly, abundant Enterobacteriaceae, decreased intestinal biodiversity and decreased intestinal levels of 
butyrate are all associated with inflammatory bowel disease, which is much less common in non-Western countries [32,107].
Non-dietary perturbations, such as antibiotics and other pharmaceuticals, also profoundly affect both host and microbiome. A study 
of mice given long-term, sub-therapeutic doses of antibiotics found large shifts in the microbial community that led to an increase in 
SCFAs. These in turn contributed to a corresponding increase in host adiposity, although the mice did not eat more [11]. Higher doses 
of antibiotics disrupt even more of a host’s endogenous microbial community, potentially leaving human patients susceptible to 
opportunistic infections such as Clostridium difficile, which can precipitate a vicious cycle of microbial community disruption [108].
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habitat investigated for atopic skin diseases [44], the gut 
microbiome’s  extensive  interaction  with  the  immune 
system  has  also  led  to  it  being  indirectly  linked  with 
atopic manifestations and sensitization [17], and directly 
with  atopic  dermatitis  in  infants  [18].  These  studies 
revealed  several  microbes,  such  as  Bifidobacterium, 
Staphylo  coccus, Escherichia coli and Clostridium difficile, 
that were associated with a higher risk of atopic derma-
titis  in  children,  albeit  not  yet  with  a  functional 
explanation. Interestingly, maternal intestinal and vaginal 
Bifidobacteria, one of the most important groups of early 
life microbes, have an incompletely characterized influ-
ence on the establishment of Bifidobacteria during infant 
gut colonization [45,46]. A recent cohort study investi-
gat  ing  the  influence  of  maternal  gut  microbiota  on 
wheezing  in  early  childhood  found  an  association 
between higher total maternal aerobes and Enterococci 
with increased risk of infant wheeze. A core concept in 
the  hygiene  hypothesis  is  that  microbial  exposures  in 
early life may ‘tune’ immune responses and ensure host-
immune homeostasis over the human lifetime. CD4+ T-
helper cell and innate lymphoid cell populations and their 
effectors may be one component of this [41], and early 
life responses to specific microbial clades may participate 
in or trigger activation of these immune responses.
Disorders of the brain-gut axis
Bidirectional communication between the brain and the 
gut has long been recognized [47], and has become the 
focus  of  increasing  research  on  the  ‘microbiome-gut-
brain  axis’  [15].  Just  as  the  microbiome  affects  the 
physical  development  of  the  gut,  it  can  also  influence 
mammalian brain development [48]. During adult life in 
rodents and insects, the composition of the gut micro-
biome has been found to influence a variety of complex 
behavioral  traits,  including  anxiety  [49]  and  mating 
preferences [50]. Potential mechanisms have been identi-
fied  for  associations  between  stress-related  disorders 
(such as anxiety and depression) and the gut microbiome 
in laboratory mice [51]. In this study, for example, GABA 
transcriptional activity was found to be stimulated via the 
vagus  nerve  by  Lactobacillus  rhamnosus.  Preliminary 
results in other systems suggest that early life stress may 
result in persistent changes to the gut microbiome, which 
in  turn  can  contribute  to  symptoms  resembling  those 
seen in human psychiatric disorders [52]. Combining this 
with microbial metabolic responses to host hormones, as 
discussed earlier, and ongoing studies of the microbiome 
in weight loss [53], it seems likely that microbial products 
will be found to have a role in hunger signaling and host 
metabolic regulation as well.
One of the clearest links between the gut microbiota 
and neural disorders is in multiple sclerosis, by way of an 
autoimmune  reaction.  Multiple  sclerosis  is  a  chronic 
inflammatory disease of the nervous system notable for 
its T-cell responses to components of nerve fiber myelin 
sheaths  [54].  Several  loci  associated  with  multiple 
sclerosis by GWAS are at or near genes with roles in T-
cell-mediated  immunity,  and  gut-resident  viruses  have 
been  suggested  as  initial  triggers  of  this  autoimmune 
response [55]. Mycobacteria and their cell extracts have 
been implicated in a surprisingly wide range of immuno-
regulatory  processes,  and  in  particular  are  capable  of 
suppressing central nervous system autoimmunity in the 
encephalomyelitis  mouse  model  by  altering  T-cell 
migration, suppressing the IL-17 response, and inducing 
apoptosis of activated T cells [56]. The Bacillus Calmette-
Guérin vaccination, which is prepared from an attenuated 
Mycobacterium  bovis  strain,  was  associated  with 
decreased  multiple  sclerosis  flare  severity  [57],  and 
bacterial  lipopolysaccharide  was  also  shown  to  protect 
mice  from  central  nervous  system  inflammation,  by 
promoting  the  growth  of  neuroprotective  T  regulatory 
cells [58]. These findings are suggestive of host responses 
that may be triggered by metabolic or cellular com  po  nents 
of  the  endogenous  microbiota,  but  to  date  no  specific 
microbial molecules have been identified as causative.
Functional profiling of the microbiome
The roles of the gut microbiota in inflammatory condi-
tions have begun to be unraveled by functional profiling, 
or  the  assessment  of  host  and  microbial  bio  molecular 
activity in tandem with microbial community structure. 
Assessment  using  nucleotide  sequencing  is  typically  a 
two-step  process.  First,  genes,  proteins,  or  protein 
families in the community (and sometimes in the host) 
are  quantified;  second,  individual  gene  families  are 
merged  into  higher-level  pathways,  such  as  metabolic 
pathways and functional modules. There are several ex-
peri  mental assays and computational methods designed 
to  accomplish  these  steps,  and  the  choice  of  method 
depends on the nature of the microbial community under 
investigation, as well as the sequencing data available to 
describe it. Considerations in the choice and application 
of  analysis  methods  are  briefly  summarized  here  and 
reviewed in depth elsewhere [59].
Functional information can be gleaned from almost any 
whole-community experimental data type; broadly, 16S 
rRNA gene sequencing [60], metagenomic or metatrans-
criptomic shotgun sequencing [61], metaproteomics [62] 
and/or  metabolomics  [63].  Host  genetics  and/or  gene 
expression can also be considered, and host products are 
typically included in metabolite, protein, and sometimes 
RNA  datasets.  Most  initial  data  acquisition  and  infor-
matics are the same for whole-community studies as for 
single-organism studies, except that first, samples must 
be  handled  with  care  in  order  to  preserve,  lyse  and 
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[64,65], and second, computational interpretation in the 
presence  of  multiple  underlying  genomes  can  be 
challeng  ing.  Metagenomics  and  metatranscriptomics 
(together meta’omics) currently represent the most cost-
effective balance between functional and structural data.
Meta’omic  data  are  typically  interpreted  by  first 
assigning  sequences  to  gene  families  [59].  This  can  be 
done by assembling short reads into contigs and identi-
fying protein-coding sequences (CDSs, using approaches 
comparable to annotating single genomes), or reads can 
be assigned directly to gene or protein families. The latter 
approach  may  either  map  reads  to  annotated  CDSs  in 
microbial reference genomes, or they may be searched 
against  databases  of  characterized  protein  families.  In 
either  case,  the  result  is  a  profile  of  microbial  gene 
families present in a community and their relative meta-
genomic or metatranscriptomic abundances. Gene family 
identification systems amenable to this process include 
the KEGG Orthology, COG [66], NOG [67], Pfam [68] 
and  UniRef  [69].  Each  of  these  satisfy  the  necessary 
criterion of a database of systematically identified protein 
sequence groups, with each individual sequence repre-
senting a family member within an individual organism. 
For  communities  described  by  16S  sequencing  data 
rather  than  shotgun  data,  direct  inferences  cannot  be 
made  about  the  CDSs  present  in  the  community,  and 
instead  one  must  rely  on  inferring  the  presence  of 
particular  functions  by  associating  16S  sequences  with 
gene content from annotated reference genomes [70].
Individual gene families profiled in any of these ways 
can  then  be  hierarchically  organized  for  ease  of  inter-
pretation,  just  as  individual  microbes  are  organized 
taxonomically or phylogenetically. This is a critical step, 
as  catalogs  typically  describe  anywhere  from  tens  of 
thousands  to  millions  of  gene  families  in  the  gut 
microbiome, but no pathway catalogs exist so far that are 
specifically appropriate to microbial communities. Data-
bases developed for single organisms do help this effort, 
such  as  KEGG  [71],  MetaCyc  [72]  and  SEED  [73]. 
Integrated bioinformatics pipelines have been developed 
to streamline the multi-step processes described above, 
including  IMG/M  [74],  MG-RAST  [75],  MEGAN  [76] 
and  HUMAnN  [77].  Each  of  these  procedures  for 
functional  sequence  analysis  provides  researchers  with 
an option for translating raw meta’omic sequence data 
into a more easily interpreted profile of the functional 
potential of a microbial community.
Functional profiling of the microbiome can be a time-
consuming process for samples characterized by a large 
amount of sequence data, as mapping these sequences to 
a gene family or reference genome databases is compu-
tationally intensive. However, once this mapping step is 
completed, subsequent analyses (such as merging gene 
families into pathways) proceed quickly, and can rapidly 
produce clinically relevant results. For example, screen-
ing an individual’s gut microbiome profile or the micro-
biome  of  an  infection  for  known  antibiotic-resistance 
genes  [78]  can  illuminate  the  resistance  potential  of  a 
microbial  community,  informing  treatment  options.  In 
addition,  profiling  the  enzymatic  composition  of  a 
patient’s gut microbiome may indicate how the cells in 
that  community  will  interact  with  pharmaceutical 
interventions; for example, whether they will metabolize 
them to inactive or potentially hazardous forms [79,80]. 
Last  but  not  least,  the  early  stages  of  diseases  with 
microbial  involvement  are  often  not  associated  with 
dramatic changes in microbial community composition. 
However, the community’s functional profile may reveal 
disease-linked perturbations at a much earlier stage of 
disease  progression,  leading  to  the  possibility  of  using 
functional  profiling  to  generate  biomarkers  for  disease 
diagnosis (Figure 1).
Functional profiling case studies in health and 
disease
A comprehensive example of functional interpretation of 
the  human  microbiome  can  be  found  in  the  Human 
Microbiome Project (HMP), which provides both experi-
mental protocols [81] and computational pipelines [1] for 
assessing the gut and other body sites. The results of the 
HMP  provide  a  useful  reference  for  gut  microbiome 
function in health, providing a variety of public data from 
a  cohort  of  242  individuals,  including  both  16S  rRNA 
gene and metagenomic shotgun sequencing [82] for the 
analysis  of  microbial  communities  and  functional  pro-
files. All subjects were clinically screened to ensure a high 
level of health [83], and these data represent a powerful 
set  of  tools  for  meta-analysis  alongside  new  disease-
focused studies [8]. Within the study itself, it was shown 
that  metagenomic  carriage  of  metabolic  pathways  was 
stable among individuals even when microbial compo-
sition  was  not,  and,  of  the  recorded  metadata,  racial/
ethnic  background  showed  one  of  the  strongest  asso-
ciations between clinical metadata and either pathways 
or microbes. The magnitude of this effect was larger than 
that of age in this cohort, in which diet was not deeply 
characterized;  these  two  factors  have  been  associated 
independently  with  microbiome  composition  in  other 
studies [6,32]. On the basis of these data [1], 118 stool 
samples  from  healthy  individuals  were  profiled,  high-
light  ing  a  core  gut  microbiome  that  consists  of  stable 
pathways that are present despite variation in microbial 
abundances  (Figure  2).  These  findings  thus  specify  the 
range of normal structural and functional configurations 
in  the  microbial  communities  of  a  healthy  Western 
population,  and  they  provide  a  framework  for  future 
studies of human microbiome function.
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A companion project within the HMP characterized the 
function  and  composition  of  the  digestive  tract  sites 
assayed  by  the  project,  comprising  ten  distinct  body 
habitats (in the mouth, oropharynx and colon [84]). These 
microbial habitats formed four related areas of microbial 
community  configurations:  tooth  hard  surfaces;  two 
distinct  types  of  oral  soft  tissues  and  environments 
(cheek/gingiva/palate versus throat/tonsils/tongue/saliva); 
and the gut, as represented by stool samples. Metabolic 
profiling revealed a set of ‘core’ digestive tract pathways 
enriched  in  abundance  throughout  these  communities, 
including pathways involved in the acquisition and export 
of  metals,  and  cytochrome  c  heme  lyase,  an  enzyme 
involved in porphyrin and chlorophyll metabolism. These 
pathways  were  unique  in  that  most  genes  encoding 
exporters needed for heme tolerance (such as MtrCDE 
and  HrtAB)  were  not  significantly  associated  with 
specific organisms in the study, and the gene encoding 
hemerythrin (responsible for oxygen transport in specific 
organisms) was detected at multiple body sites but was 
highly  enriched  in  stool.  Conversely,  each  of  the  four 
habitats was also enriched in more niche-specific meta-
bo  lism,  such  as  the  β-glucosidase  pathway  in  stool 
(involved in cellulose breakdown to β-d-glucose), glyco-
lysis and pyruvate generation by glucose metabolism, and 
several  pathways  for  ammonia  utilization  (such  as  the 
urea cycle and ornithine biosynthesis), as well as methane 
production. The oral cavity, conversely, showed enrich-
ment  for  energy  harvest  pathways  reliant  on  simple 
sugars (mannose, fructose, trehalose, and so on) and in 
many cases oxidative metabolism (especially when con-
trasting, for instance, supra- versus sub-gingival plaques). 
While  in  many  cases  these  pathways  were  broadly 
phylogenetically distributed among diverse clades, others 
were  tightly  tied  to  just  a  few  microbes  (for  example, 
hydrogen sulfide production by the Veillonella, Seleno­
monas and Prevotella genera).
Figure 2. The core gut microbiome consists of stable pathways present despite variation in microbial abundances. Profiles of 118 stool 
samples from healthy individuals, showing the relative abundances of microbial organisms (red), inferred microbial pathways [70] (green), and 
microbial pathways after randomization (blue, all data from [1]). All relative abundances are shown as median and interquartile range across all 
samples (y-axis) ranked by median (x-axis) and square-root (sqrt) scaled for visualization. As illustrated by several studies (for example, [1,89]), a 
stable distribution of habitat-adapted microbial pathways is maintained on a functional level (green) rather than on a phylogenetic level (red). 
Random assignment of microbes to samples followed by re-inference of functional potential (blue) results in a metagenome that is more variable, 
more skewed, and of distinct composition from that in the observed ‘core’ of gut microbiome functions.
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Both  protective  immune  responses  and  dysregulation 
during autoimmunity are activated by signals initiated by 
innate  immunity  and  driven  by  microbial  stimuli  [85]. 
Many studies have thus investigated microbial function 
in  the  gut  microbiome  in  these  diverse  autoimmune 
diseases, with several recent examples including inflam-
ma  tory bowel disease [31,32,86,87], rheumatoid arthritis 
[36],  and  allergy  and  atopy  [18,42,88]  (as  described 
earlier), as well as metabolic syndrome [89,90] and neuro-
logical disorders [15,47-49]. As a T-cell-mediated meta-
bolic disease, type 1 diabetes is another prime candidate 
for  involvement  of  the  gut  microbiota  [5,10,91].  Much 
current work on the function of the gut microbiome in 
type 1 diabetes relies on the non-obese diabetic (NOD) 
mouse  model  [92,93],  a  well-known  system  in  which 
immune-mediated  pancreatic  β-cell  destruction  is 
triggered  by  gut  microbial  colonization  [93].  Table  1 
summarizes  these  and  additional  relationships  among 
microbial  organisms  and  pathways,  as  well  as  human 
genes and pathways, that are known to be involved in 
these inflammatory conditions.
A recent study investigated the human gut microbiome 
in malnourished children, specifically in kwashiorkor, a 
childhood  protein-deficiency  disease  [6].  The  authors 
first identified nine well-nourished twin pairs and 13 twin 
pairs who became discordant for kwashiorkor over the 
study period of 18 months. Fecal metagenomics showed 
age to be the greatest determining factor in gut microbial 
variation in healthy children, along with family member-
ship and diet. Healthy children showed a steady progres-
sion toward a consistent microbiome common to older 
children, which did not take place in subjects suffering 
from  kwashiorkor.  Surprisingly,  though,  no  significant 
changes  in  the  functional  composition  of  the  gut 
microbiome  occurred  after  treatment.  Instead,  several 
metabolic pathways were already significantly different in 
discordant twin pairs at the time of diagnosis, such as α-
mannosidase, an enzyme involved in glycan biosynthetic 
reactions  and  catabolism,  and  protein-N(PI)-phospho-
histidine-sugar phosphotransferase, an enzyme involved 
in  sugar  catalysis.  Microbial  pathways  including  β-
glucosidase and β-galactosidase activity remained signifi-
cantly different in discordant twin pairs a month after 
cessation of treatment, suggesting substantial stability of 
changes induced in the microbiome by extreme environ-
mental effects.
The authors subsequently transplanted fecal microbial 
communities from discordant twin pairs into gnotobiotic 
mice  to  identify  features  of  the  microbial  community 
structure,  metabolism,  and  host-microbial  co-metabo-
lism associated with donor health status and diet. In this 
mouse model, they found increased levels of the majority 
of SCFAs, carbohydrates, amino acids, nucleotides and 
lipid  metabolism  in  cecal  and  fecal  samples  in  mice 
receiving dietary treatment, whereas levels of several di- 
and monosaccharides (maltose, gentibiose and tagatose) 
were decreased. When the mice (both healthy and with 
kwashiorkor) started treatment, the levels of nine amino 
acids  (valine,  leucine,  isoleucine,  methionine,  phenyl-
alanine, threonine, alanine, tyrosine and serine) rapidly 
increased. After returning to a normal diet, most of these 
amino acids remained higher in healthy mice than before 
therapy, but in the kwashiorkor group, these values fell to 
pre-treatment  levels.  This  suggests  that  the  stable 
alteration  of  the  microbiome  specifically  influences  its 
future ability to maintain healthy host-microbe metabolic 
interactions.  Additionally,  the  authors  found  that  the 
urinary excretion of the tricarboxylic acid (TCA) cycle 
intermediates  2-oxoglutarate,  citrate,  succinate  and 
fumarate  were  closely  coupled  in  healthy  mice  but 
decoupled in kwashiorkor. This disruption of the TCA 
cycle  resulted  in  an  increased  succinate-to-fumarate 
ratio, possibly from inhibition or depletion of succinate. 
The authors suggested that this might be the result of 
kwashiorkor-specific  generation  of  chemical  products 
selectively inhibiting TCA cycle enzymes, making energy 
metabolism an even more extreme challenge for children 
with  kwashiorkor  exposed  to  a  micro-  and  macro-
nutrient-deficient, low-calorie diet.
This result provides an informative case study in that 
it  traces  a  microbiome-linked  human  disease  from 
popu  lation-level  epidemiology  through  a  validated 
molecular  mechanism  to  potential  diet-driven  treat-
ment.  Although  the  resulting  human  health  recom-
mendations  remain  to  be  validated,  it  provides  an 
example of a case in which the three major elements of 
functional gut microbiome profiling were used to derive 
an actionable result: broad sequencing-based surveys of 
the  gut  microbiome  in  a  human  population,  deep 
sequencing  and  functional  assays  in  a  gnotobiotic 
mouse  model  to  detail  metabolic  mechanisms,  and 
subsequent follow-up profiling of a potential treatment 
in  humans.  Even  in  this  relatively  straightforward 
example, interplay between environ  mental factors, diet, 
variable  microbial  composition  and  age  must  all  be 
taken  into  account  to  understand  host-microbiome 
interactions in human disease.
Functional profiling in the future: a perspective
The  past  five  years  have  seen  an  explosion  of  human 
microbiome  studies,  most  of  which  have  associated 
changes in microbial ecology with human health or the 
environment [1,7,8,81,89,94]. In almost no cases, though, 
do we yet know the causality, mechanism or relevance of 
these microbial shifts. In the few instances where specific 
biomolecular  interactions  have  been  addressed  [95,96], 
they have begun to effectively indicate routes by which 
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therapeutically targeted.
The  recent  history  of  cancer  genomics  suggests  an 
important  parallel  for  the  next  steps  in  translating 
human  microbiome  studies  to  the  clinic.  Early  des-
criptive  work  in  cancer  functional  profiling  proved 
difficult  to  interpret  or  act  on,  and  only  a  detailed 
understanding  of  molecular  activities  within  the 
complex, mixed cellular population of a tumor allowed 
the  creation  of  effective  targeted  therapies.  The  same 
necessity  for  deep  biomolecular  characterization  is 
likely to hold true in the complex, mixed cellular popu-
lation of a microbial community.
To this end, microbiome studies now have experimental 
design  options  that  allow  the  integration  of  both 
descriptive and functional assays, as well as more con  ve-
nient and holistic computational interpretation. Researchers 
must  take  advantage  of  these  to  test  specific,  well-
controlled hypotheses in human subjects, model systems 
(mouse,  zebrafish  and  others  [97]),  and  in  vitro  (for 
example, cell culture and functional screens). Epithelial 
cell  lines  and  synthetic  systems  (such  as  co-culture, 
microfluidics  and  organoids)  represent  an  intriguing 
untapped resource. Conversely, large population surveys 
relating microbial structure to function (transcripts and 
proteins)  have  also  not  yet  been  performed  and  will 
establish an important baseline, building on references 
such as the HMP and MetaHIT.
Analytical  limitations  remain  to  be  overcome  in  the 
translation of functional microbiome surveys to human 
health,  both  in  our  understanding  of  basic  biological 
mecha  nisms and in our ability to leverage these data for 
clinical use. The former will require substantially more 
comprehensive integrative models of multi-microbe and 
host-microbe signaling, metabolic interaction, immuno-
logy  and  ecology  than  are  available  today.  The  latter, 
again not unlike personalized cancer therapies, in many 
cases  still  needs  high-reliability,  large-effect-size 
predictors of disease risk and outcome in humans to be 
clinically  actionable.  To  address  these  challenges, 
carefully designed pre-clinical experimental systems are 
needed,  particularly  longitudinal  prospective  and 
outcome-based  studies  in  human  populations  to  detail 
the dynamics of microbial function during disease onset, 
treatment and resolution. In the future, in combination 
with  novel  com  pu  tational  models  and  the  continued 
incorporation of sequencing technologies into the clinic, 
such  investi  gations  will  lead  us  towards  a  deeper 
understanding  of  microbial  communities  and  their 
functional roles in health, inflammation and disease.
Table 1. Published relationships among microbial clades, pathways, and human genes and pathways involved in 
autoimmune diseases 
Disease  Microbes  Microbial pathways  Host pathways  Representative host genes  References
Inflammatory 
bowel disease
Enterobacteriaceae, 
Roseburia, 
Ruminococcaceae
Glutathione metabolism and 
transport, riboflavin metabolism, 
short-chain fatty acid metabolism
Autophagy, Th17, 
T-cell responses and 
cytokines, JAK-STAT, 
NF-kB, microbial 
sensing
ATG16L1, CARD9, DUOX2, 
IL10, IL23R, IRGM, FUT2, 
MHC, NCF4, NOD2 
[3,25,31,32, 
86,87, 
107,109]
Type 1 diabetes Akkermansia, 
Bacteroidales, 
Lactobacillaceae
Amino acid metabolism, 
secondary metabolite 
biosynthesis, butyrate production, 
carbohydrate metabolism, 
glycan biosynthesis and 
metabolism, lactate production, 
lipid metabolism, nucleotide 
metabolism
Innate immune 
signaling, mucin, 
MyD88, Toll-like 
receptors
CTLA4, IL2RA, IFIH1, INS, 
MYD88, MHC, PTPN22, TLR
[5,91, 
110-116]
Rheumatoid 
arthritis
Bacteroides fragilis, 
Bacteroides vulgatus, 
Clostridium coccoides, 
Eubacterium rectale, 
Klebsiella, Lactobacillus, 
Porphyromonas, 
Prevotella, SFB 
 - CD40, IL-2, NF-kB 
activation, SAA or 
CCL5 signaling, 
T-cell activation and 
response
CD40, CCL21, HLA-DRB1, 
IL2, IL17, IFNG, KIF5A, MHC, 
TLR2, TLR4, TNF, TNFAIP3, 
PRKCQ
[38,117, 
118]
Multiple 
sclerosis
Epstein-Barr virus, 
Mycobacteria
 Vitamin D metabolism Vitamin D, CD4+ 
T cells
DRB1, IL2, IL7, HLA, MHC [56,57, 
119-121]
Allergy, atopy Aerobes, Bifidobacteria, 
Enterococci, 
Staphylococcus aureus, 
Escherichia coli, 
Clostridium difficile
 - IgE antibody 
regulation, vitamin D
ADAM33, ADRB2, CD14TNF, 
IL10, IL4, IL13, IL4RA, IFNG, 
FLG, FCER1B, HLA-DRB1, 
HLA-DQB1, MHC
 [17,18,45, 
46,122-128]
SFV, segmented filamentous bacteria.
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